Most Read Articles
04 Feb 2019
The carbon-chain length of saturated fatty acids appears to be an important factor in determining its role in cardiovascular health, a recent study has found.
6 days ago
Olanzapine confers a modest therapeutic effect on weight compared with placebo in adult outpatients with anorexia nervosa, a study has shown. However, it does not appear to offer significant benefit for psychological symptoms.
Pearl Toh, 3 days ago
A latest study at ISC 2019 shows that even patients with large-core stroke damage can have a good outcome after mechanical clot removal with endovascular thrombectomy (EVT), depending on the size of the infarct and time lapses between stroke onset and treatment.
Jairia Dela Cruz, 04 Feb 2019
Treatment with secukinumab results in a higher rate of remission or low-disease activity at week 16 in patients with psoriatic arthritis as compared with placebo, according to a posthoc analysis of the FUTURE 2 study. This effect is sustained at 2 years and is evident in both tumour necrosis factor inhibitor-experienced and -naïve patients.

Psoriatic arthritis manifestation impairs health-related quality of life

20 Nov 2018

Psoriatic arthritis (PsA) at time of diagnosis worsens health-related quality of life (HRQOL) in comparison to the reference population, a Dutch study has found. Tender joints, enthesitis at clinical examination and back pain as indicators of pain affect HRQOL.

Of 405 patients included in the study, 320 had peripheral arthritis (78 monoarthritis, 151 oligoarthritits and 91 polyarthritis), 39 had dactylitis, 37 had enthesitis and nine had axial disease.

Mean scores of Short Form-36 (SF-36) domains were lower compared to the reference population and similar across subtypes of arthritis. Worse SF-36 scores were associated independently with a higher number of enthesitis locations and tender joints, and with the presence of chronic back pain. Moreover, psoriasis and dactylitis did not correlate with worse score.

This study analysed data collected at time of diagnosis from PsA patients included in the Dutch southwest Early Psoriatic Arthritic (DEPAR) cohort. Eight domains of the Medical Outcomes Study SF-36 questionnaire were used to assess HRQOL.

Patients were grouped according to primary manifestation in arthritis subtypes (ie, mono-, oligo- or polyarthritis) and other subtypes (ie, enthesitis, dactylitis and axial disease). The investigators determined the presence of arthritis, enthesitis, dactylitis, psoriasis and chronic inflammatory back pain in all patients. They determined associations between PsA manifestations and HRQOL using multivariable linear regression.

“PsA is a multifaceted disease. Affecting joints, skin, entheses, and dactylitis, its effect on HRQOL could be substantial,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
04 Feb 2019
The carbon-chain length of saturated fatty acids appears to be an important factor in determining its role in cardiovascular health, a recent study has found.
6 days ago
Olanzapine confers a modest therapeutic effect on weight compared with placebo in adult outpatients with anorexia nervosa, a study has shown. However, it does not appear to offer significant benefit for psychological symptoms.
Pearl Toh, 3 days ago
A latest study at ISC 2019 shows that even patients with large-core stroke damage can have a good outcome after mechanical clot removal with endovascular thrombectomy (EVT), depending on the size of the infarct and time lapses between stroke onset and treatment.
Jairia Dela Cruz, 04 Feb 2019
Treatment with secukinumab results in a higher rate of remission or low-disease activity at week 16 in patients with psoriatic arthritis as compared with placebo, according to a posthoc analysis of the FUTURE 2 study. This effect is sustained at 2 years and is evident in both tumour necrosis factor inhibitor-experienced and -naïve patients.